El interés en corto de Applied DNA Sciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Applied DNA Sciences. Los datos de interés en corto se actualizan cada dos semanas.

Applied DNA Sciences (NASDAQ:APDN) Bolsa, Informe de interés en corto

Applied DNA Sciences

Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) nd ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.

Applied DNA Sciences, Inc. - Common Stock

Applied DNA Sciences Inc

<h3>Gainers</h3>
<ul>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock moved upwards by 38.8% to $13.82 during Monday's regular session. The company's market cap stands at $488.1 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) shares moved upwards by 36.58% to $0.74. The company's market cap stands at $54.2 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock moved upwards by 32.73% to $0.47. The company's market cap stands at $35.5 million. </li>
<li>Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) stock rose 27.82% to $4.87. The company's market cap stands at $7.5 million. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock increased by 16.44% to $4.03. The company's market cap stands at $483.5 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock moved upwards by 16.35% to $0.59. The market value of their outstanding shares is at $22.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock decreased by 28.8% to $0.46 during Monday's regular session. The company's market cap stands at $6.0 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares declined by 27.4% to $0.67. The company's market cap stands at $6.9 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock decreased by 25.87% to $0.36. The company's market cap stands at $2.6 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares decreased by 20.04% to $1.48. The company's market cap stands at $8.7 million. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares fell 19.87% to $16.07. The market value of their outstanding shares is at $864.0 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 18.81% to $0.36. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APDN

BNOX

CAPR

ALPS ETF Trusthen & Steers Global Realty Majors ETF

HCWB

PRME

PRTA

PSTV

XBIO

12 Health Care Stocks Moving In Monday's Intraday Session

<a href="https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.">https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.</a>
&nbsp;
Los Angeles County health officials are reporting a significant uptick in mpox cases, prompting renewed calls for vaccination among&nbsp;high-risk&nbsp;groups.
The County's Department of Public Health announced that 52 mpox cases were reported in the past four weeks, compared to 24 in the previous&nbsp;four-week&nbsp;period.&nbsp;
About 70% of new cases in the last six months occurred in&nbsp;unvaccinated&nbsp;individuals.
Health officials strongly recommend vaccination for several high-risk groups, including men and transgender people who have sex with men or transgender persons, persons of any gender or sexual orientation who have sex or intimate physical contact with others in association with large public events or engage in commercial and/or transactional sex, and those living&nbsp;with&nbsp;HIV.
"Vaccination is an important tool in preventing the spread of mpox," the County health department said in a statement. The two-dose JYNNEOS vaccine is available at pharmacies for insured residents and at Los Angeles County Department of Public Health Clinics for free&nbsp;without&nbsp;appointments.
Officials advise residents to practice safe sex, limit sexual partners, and avoid intimate contact with anyone showing mpox symptoms, which include rash, fever, and swollen lymph nodes. Additional prevention measures include asking partners about symptoms, reducing the number of partners, and proper use of condoms&nbsp;and&nbsp;gloves.
The County emphasizes the importance of testing for those who develop symptoms consistent with mpox. The Department of Public Health is collaborating with healthcare providers and community organizations to intensify surveillance, contact tracing, and outbreak investigations to&nbsp;curb&nbsp;transmission.
Mpox, previously referred to as Monkeypox, is mainly spread through close physical contact. Residents seeking more information can visit<a href="http://ph.lacounty.gov/mpox"> ph.lacounty.gov/mpox</a> or call the Department of Public Health Call Center&nbsp;at&nbsp;1-833-540-0473.

Biotech

Macro Economic Events

News

Economics

General

AEMD

CMRX

GOVX

MRNA

TNXP

VRAX

'Mpox Cases Double In Los Angeles County, Health Officials Urge Vaccination; Los Angeles County Public Health Officials Report Increase, Recommend Prevention Measures' - Pasadena Now

<a href="https://www.youtube.com/watch?v=ZFW3ONApp4w" title="https://www.youtube.com/watch?v=ZFW3ONApp4w">https://www.youtube.com/watch?v=ZFW3ONApp4w</a>

Macro Notification

Trading Ideas

Biden On Sudan Says End This War Now; Let's Move Quickly To Face Mpox Outbreak In Africa

-Reuters Citing Senior Administration Official

President Biden Will Announce Donation Of 1M MPox Vaccine Doses, At Least $500M To African Countries To Support Their Response To Outbreak

CDC Says No Cases Of Clade IA Mpox Have Been Reported Outside Central African Countries Where Clade IA MPVX Is Endemic

<a href="https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.">https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.</a>
&nbsp;
EMA has recommended extending the indication of the smallpox and mpox vaccine <a href="https://www.ema.europa.eu/node/65501">Imvanex</a> to adolescents from 12 to 17 years of age.
Imvanex is already authorised in the European Union (EU) to protect against smallpox, mpox and the disease caused by the vaccinia virus in adults. It contains a live, highly weakened form of a virus called "modified vaccinia virus Ankara" (MVA-BN), which is related to the smallpox virus. EMA's human medicines committee (CHMP) based the recommendation to extend the use of Imvanex to adolescents on the <a href="https://www.clinicaltrials.gov/study/NCT05740982">interim results of a study</a> that compared the vaccine's ability to generate an immune response (produce virus-specific antibodies) in 315 adolescents and in 211 adults.
The immune response in adolescents was similar to adults. Therefore, it is inferred that the vaccine will provide similar protection in adolescents to that expected in adults. According to the submitted data, the safety profile of Imvanex in adolescents was comparable to that seen in adults and no additional risk has been identified. As part of its recommendation, EMA has requested the marketing authorisation holder to submit the final results of the study by 30 May 2025 to further characterise the information about safety in adolescents.
The Agency's assessment has important implications for the global response to the mpox outbreak in the Democratic Republic of the Congo (DRC) and other countries, which was <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">declared a public health emergency of international concern (PHEIC)</a> by the World Health Organization (WHO) on 14 August 2024.
EMA is the regulatory agency of record for <a href="https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox">prequalification of this vaccine by WHO</a> on 13 September 2024. This means that CHMP's assessment constitutes the basis for WHO prequalification approval to facilitate timely and increased access to this vaccine in communities with urgent need. Previously, EMA's assessment was also taken into account by the national regulatory authority of the DRC in the fast-track approval of the vaccine. In addition, WHO has cooperated in EMA's assessment of the extension of indication in adolescents, a population that is particularly vulnerable to mpox.
Mpox is a disease that is transmitted to people by animals, mainly rodents, but can also spread between people with direct contact. It is endemic in certain parts of Central and West Africa. The current surge in cases in the DRC and several neighbouring countries is driven by the mpox clade I strain that is known to cause a more severe form of mpox in humans than the mpox clade II strain that spread during the 2022/2023 PHEIC. Mpox can be fatal for people with weak immune systems.
Data indicate that Imvanex protects against both the clade I and clade II mpox strains.
In the EU, decisions on how vaccinations should be given are the prerogative of the expert bodies guiding vaccination campaigns in each Member State. The European Centre for Disease Prevention and Control (ECDC) <a href="https://www.ecdc.europa.eu/en/infectious-disease-topics/mpox/rapid-scientific-advice-public-health-measures-mpox-2024">published advice for public health authorities for mpox</a> on their website.

Global

'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA

Applied DNA Regains Compliance With Nasdaq Minimum Bid Price Requirement

- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing -
STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / <a href="https://pr.report/2ok4">Applied DNA Sciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week:
<a href="https://pr.report/2ok5">3rd Annual mRNA Process Development &amp; Manufacturing Summit</a> - members of Applied DNA's Biotherapeutics Sales and Business Development teams (collectively 'LineaRx,' a majority-owned Applied DNA company) will attend the 3rd Annual mRNA Process Development &amp; Manufacturing Summit taking place September 17-19, 2024.
LineaRx will present its Linea&#x2122; IVT platform - a combination of an enzymatically produced DNA template (Linea&#x2122; DNA IVT template) coupled with a next-generation RNA polymerase (Linea&#x2122; RNAP) - as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
<a href="https://pr.report/2ok6">Lunch/Learn</a> with <a href="https://pr.report/2ok7">Kudo Biotechnology</a> - LineaRx and mRNA CDMO partner Kudo Biotechnology will co-host a seminar luncheon to present data from a proof-of-concept study and a case study to demonstrate how Linea IVT can support rapid manufacturing of dsRNA-mitigated mRNA. The Lunch/Learn will be held on Thursday, September 19, from 11:00 a.m. - 2:00 p.m. ET at <a href="https://pr.report/2ok8">MassBio</a> and will be webcast-accessible <a href="https://pr.report/2ok9">here</a>.

Events

Applied DNA To Showcase Linea IVT As A High-Yield, dsRNA-Mitigated Platform For the GMP Manufacture Of RNA At The 3rd Annual mRNA Process Development & Manufacturing Summit September 17-19, 2024

- Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA -
STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / <a href="https://pr.report/2n6a">Applied DNA Sciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than $500,000 for a quantity of Linea&#x2122; DNA from a global manufacturer of in vitro diagnostics (IVDs). The follow-on order was placed under a long-standing supply agreement for the bulk manufacture of Linea DNA (non-therapeutic) used in the manufacture of a cancer diagnostic test. Applied DNA expects to deliver on the order over four quarterly shipments in calendar 2025.

Contracts

Reported Earlier, Applied DNA Receives Linea DNA Follow-On Order Valued At More Then $500K From Global Manufacturer Of IVDs For Cancer Diagnostic Application

US To Stay Committed In Bringing Mpox Outbreak Under Control

Morocco Records First Case Of Mpox

Applied DNA Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>), through its subsidiary Applied DNA Clinical Labs (ADCL), has expanded its clinical testing services for mpox (formerly known as monkeypox). Shares rose some 37% to $1.76 Wednesday morning following a <a href="https://www.benzinga.com/pressreleases/24/09/ac40813623/applied-dna-launches-mpox-clade-i-and-clade-ii-testing-service">press release</a> from the company. Applied DNA Sciences says the new service includes detection of both Mpox Clade I and Clade II, following approval from regulatory bodies like the New York State Department of Health and the FDA. 
Applied DNA Sciences also says this move aims to help New York and other states combat the rising Mpox threat by enhancing access to testing. ADCL&#8217;s Linea Mpox Virus 1.0 Assay, initially approved in 2022 for detecting Clade II, was recently validated to detect Clade I as well. Testing will be conducted at ADCL's lab in Stony Brook, NY.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40812986/inflation-slows-to-2-5-in-august-lowest-rate-since-february-2021-core-index-remai">Historic Inflation Data Hits Lowest Level Since February 2021 — But One Segment Remains Stubbornly High</a>
<h2 class="wp-block-heading">How To Buy APDN Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Applied DNA Sciences&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, APDN has a 52-week high of $28.40 and a 52-week low of $0.31.

Why Applied DNA Sciences (APDN) Stock Is Skyrocketing

WIIM

Applied DNA Sciences shares are trading higher after the company announced it launched the Mpox Clade I and Clade II testing service.

<a href="https://pr.report/2gpx">Applied DNA Sciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) (Applied DNA), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched an expansion of its clinical testing services for the detection of Mpox (formerly monkeypox) to include testing for both mpox Clade I and Clade II. The launch of the expanded mpox testing service comes after ADCL's interaction with relevant regulatory bodies, including the New York State Department of Health (NYSDOH) and the U.S. Food and Drug Administration (FDA).

Applied DNA Launches Mpox Clade I And Clade II Testing Service

Applied DNA Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NYSE">APDN</a>) short percent of float has risen 142.36% since its last report. The company recently reported that it has 1.73 million shares sold short, which is 16.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Applied DNA Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725986715_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Applied DNA Sciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Applied DNA Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Applied DNA Sciences's peer group average for short interest as a percentage of float is 4.20%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Applied DNA Sciences's Recent Short Interest

CDC Says There Have Been No Reported Cases Of Clade I Mpox In The U.S. As Of September 6; In The U.S., Clade II Mpox Is Still Circulating At Low Levels

<a href="https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926">https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926</a>
&nbsp;
Senior Biden administration officials said Friday that the United States is preparing for the possible arrival of <a href="https://www.nbcnews.com/health/health-news/mpox-strain-spreads-cdc-who-stronger-warnings-rcna165155">a more severe version of mpox</a>, which has taken off in the Democratic Republic of Congo and other countries in Africa resulting in more than 600 deaths there.
As of Thursday, there have been more than 24,800 reported cases of this version of the virus, <a href="https://www.nbcnews.com/health/health-news/mpox-virus-outbreak-symptoms-2024-spread-rcna166778">known as clade 1</a>, so far this year, the World Health Organization said at a separate briefing Friday.&nbsp;The WHO declared the outbreak a<a href="https://www.nbcnews.com/health/health-news/who-declares-mpox-global-public-health-emergency-second-time-rcna166601"> global health emergency</a> in August.
Last month,<a href="https://www.nbcnews.com/health/health-news/sweden-confirms-first-case-mpox-strain-congo-rcna166763"> Sweden confirmed a case of clade 1</a>, the first known case outside of Africa, followed by a case in Thailand several days later. Both patients had spent time in Africa.
A different version of mpox, clade 2, triggered a global outbreak in 2022 and a surge of cases in the U.S. Clade 1 is more severe and can kill up to 10% of people infected, though recent death rates have been around 1% to 3.3%, <a href="https://www.cdc.gov/poxvirus/mpox/about/index.html">according to the CDC.</a>
On a call with reporters, senior administration officials said that as infections have risen in Africa, the U.S. has been gearing up for its own cases.&nbsp;
"We've been preparing for the arrival of clade 1 in the United States for many months now, especially as we saw the outbreak in DRC and neighboring countries accelerate," one official said.
The government is expanding its mpox surveillance efforts, primarily through wastewater analysis, and is reaching out to the medical community to educate members on what to watch for, including the severity of clade 1 and how it spreads, according to officials.
Officials said they're also making sure testing is more widely available.
Any doctor in the U.S. can order an mpox test that can be run through a national laboratory. If positive, it can be tested for clade 2. If those results are negative for clade 2, the doctor can make a presumptive diagnosis of clade 1; that diagnosis will need to be officially confirmed by the Centers for Disease Control and Prevention, according to officials.
The Jynneos mpox vaccine, given in two doses, is effective against both clade 1 and clade 2 of mpox.
The CDC's vaccine recommendation remains limited to anyone who is considered at high risk of catching the virus, mainly gay and bisexual men.&nbsp;
Most people with health insurance can get the vaccine at major pharmacy retail chains including CVS and Walgreens, the officials said. The vaccine is also available for free at public health departments and community health centers.
More vaccines are being held in the U.S. national stockpile, officials said, although they declined to say how many.&nbsp;
"There is a sufficient amount of vaccine for the U.S. population," an official said.&nbsp;
The U.S. is also working with government scientists and drug companies to develop potential new treatments. There are currently no approved treatments for mpox. The Food and Drug Administration has approved an antiviral treatment known as TPOXX for smallpox, which is closely related to mpox, although a recent clinical trial found that the drug is <a href="https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo">not effective against clade 1</a>.&nbsp;

'U.S. Prepares For Possible Arrival Of More Severe Strain Of Mpox; There Have Been Nearly 25,000 Cases Of The Clade 1 Version Of Mpox In Africa So Far This Year" - NBC

<a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523">https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523</a>
&nbsp;
Today, close to 100,000 mpox vaccine doses will arrive in the Democratic Republic of Congo (DRC), making these the first delivery of the vaccine to the country. A second delivery amounting to around 100,000 vaccines is expected to arrive in the coming days.
These vaccines are part of the 215,000 MVA-BN&#xAE; <a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4244">vaccine doses</a> that the European Commission's Health Emergency Preparedness and Response Authority (HERA) procured and pledged to share to affected countries in Africa as an immediate response to the mpox outbreak.
Via Team Europe, an additional 351,500 of doses from France, Germany, Spain, Malta, Portugal, Luxembourg, Croatia, Austria, Poland, and potentially some other Member States, will be donated to the Africa CDC to distribute to affected countries. This brings the total number of vaccine doses donated from Team Europe to at least 566,500, which includes the above 215,000 doses that were donated by HERA in cooperation with the Bavarian Nordic pharmaceutical company.
EU support for the mpox outbreak
This initiative is part of a comprehensive set of EU actions put in place as part of the EU Global Health Strategy, which represents the external dimension of a strong European Health Union and is a key component of Global Gateway, to support partners in the rest of the world.
The Commission is actively coordinating the response of EU Member States to the mpox outbreak via regular meetings of the HERA Board and the Health Security Committee, which allows prompt coordination when dealing with health threats.
The Emergency Response Coordination Centre (ERCC) is in contact with EU Member States given that, if activated, the EU Civil Protection Mechanism (rescEU) can be used to channel mpox vaccines and therapeutics to countries in need. Specialised expertise, medical items and equipment could also be deployed based on these needs.
Under the Global Gateway investment strategy, the Commission is committed to advancing public health in Africa. The Commission has focused on strengthening health systems, securing pharmaceutical supply chains, and developing local manufacturing through investment in infrastructure and a supportive regulatory environment. An example of this is the Team Europe Initiative on manufacturing and access to vaccines, medicines and health technologies (Mav+) and on Sustainable Health Security.
The European Centre for Disease Prevention and Control (ECDC) is supporting epidemiological work on the ground in the DRC, working with the Africa CDC to identify priority areas for mpox research, and is leading coordination of the Network of Major CDCs globally. HERA is also working with the Africa CDC with the aim of expanding access to mpox diagnostics and sequencing in the region, with a €9.4 million grant foreseen for early autumn.
The Commission has released €1 million in humanitarian aid to support care, prevention, epidemiological surveillance, risk communication and distribution of kits in the eastern DRC as well as €200,000 in Burundi to assist the Burundi Red Cross in preparing for and responding to the epidemic. Under the European Humanitarian Response Capacity (EHRC), in cooperation with the ECDC, two epidemiologists were deployed on 4 September to the DRC. In addition, the Commission provides regular humanitarian funding for surveillance programmes, including in Uganda and Kenya's camps and settlements and expertise to assist in the response.

'First Delivery Of Mpox Vaccine Doses From The Commission Arrive Today In The Democratic Republic Of Congo' - European Commission

Applied DNA Sciences shares are trading lower. The company announced it received a subcontract award from LRQA for a pilot isotopic testing program.

- Pilot Project To Demonstrate Effectiveness of CertainT&#xAE; for Cotton Textile Traceability -
STONY BROOK, NY / ACCESSWIRE / September 4, 2024 / <a href="https://pr.report/28l1">Applied DNA Sciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) (Applied DNA), a leader in PCR-based DNA technologies, today announced the receipt of a subcontract award from <a href="https://pr.report/28l2">LRQA</a> following a competitive tender for a pilot isotopic testing program. Under the terms of the subcontract, Applied DNA, together with its traceability partner, Isotech (a Stratum Reservoir company), will employ CertainT&#xAE; to conduct isotopic testing and analysis to support cotton traceability in Pakistan. Financial terms of the subcontract were not disclosed.
<a href="https://pr.report/28l3">CertainT</a> is Applied DNA's textiles traceability platform that uses forensic, multiple-proof-point evidence to enable source and authenticity verification of materials and products at any point as they are transformed through global supply chains. LRQA is a leading global assurance company that brings together decades of unrivaled expertise in assessment, advisory, inspection, and cybersecurity services.
The subcontract with Applied DNA was issued in support of the <a href="https://pr.report/28l4">Global Trace Protocol project</a> (the "Project"), a U.S. Department of Labor-funded initiative implemented by LRQA (known as ELEVATE during the Project's inception) that is designed to reduce child and forced labor in global supply chains through traceability. The Project engages with trace experts, global brands, Pakistan's cotton sector, and worker organizations to design, implement, and assess the pilot trace tool to improve its future application and develop publicly available commodity-agnostic trace resources for enhanced due diligence.

Applied DNA Selected By LRQA For Isotopic Testing Pilot Project In Pakistan; Financial Terms Of The Subcontract Were Not Disclosed

Bavarian Nordic rebounds as new mpox vaccine order boosts outlook

Mpox stocks in focus as Thailand reports first case in Asia linked to new strain

Tonix stock jumps on collaboration for mpox vaccine candidate

Labcorp considering ramping up mpox testing capacity: report

Trinity stock soars post-market on raised guidance, increased capacity

UNICEF issues emergency tender to secure mpox vaccines

Bavarian Nordic stock slides on Moderna mpox vaccine study

Applied DNA stock jumps amid U.S. government mpox update

Morocco reports first mpox case amid ongoing global outbreak

Applied DNA Sciences regains Nasdaq compliance

APNHF

BVNKF

BVNRY

CODX

RHHBF

RHHBY

SIGA

TRIB

Press Releases

CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit

Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

Earnings

Applied DNA Announces Third Quarter Fiscal Year 2024  Financial Results

Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I

Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan

Applied DNA Launches Mpox Clade I and Clade II  Testing Service

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit

Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application

Comments

Applied DNA Sciences

Interés en corto

Applied DNA Sciences (NASDAQ:APDN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL